Novel First-in-Class Drug Promising in Early ADHD Study
Medscape
A novel orexin-2 receptor agonist, ALKS 7290, showed clinically meaningful improvements in ADHD symptoms in a phase 1B study, with significant reductions in severity scores observed as early as day 6. Both 20-mg and 50-mg doses were well tolerated, with no serious adverse events. This marks the first clinical evidence of orexin receptor agonists' potential in treating ADHD.
All articles from 23 September 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.